Drug Profile
Research programme: theta defensins - Oryn Therapeutics
Alternative Names: Orynotides; OTP-300; OTP-602Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Oryn Therapeutics
- Class Antibacterials; Antifungals; Antimicrobial cationic peptides; Macrocyclic compounds; Peptide antibiotics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bacterial infections
- Research Autoimmune disorders
Most Recent Events
- 04 Sep 2023 Early research development is ongoing in Autoimmune disorders in USA
- 04 Sep 2023 Preclinical development is ongoing in Bacterial infections in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Bacterial-infections in USA